ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2391 • ACR Convergence 2024

    Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise

    Güllü Sandal Uzun1, Emily Apsley2 and David Isenberg2, 1University College London, London, England, United Kingdom, 2University College London, London, United Kingdom

    Background/Purpose: The anti-nuclear antibody (ANA test)  is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
  • Abstract Number: 2410 • ACR Convergence 2024

    A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures

    Kathryn Connelly1, Rachel Koelmeyer1, Darshini Ayton1, Lavanya Rajagopala2, Ambika Wahklu2, John May3, Raychel Barallon4, Rangi Kandane-Rathnayake5, Laura Eades1, kate Gregory1 and Eric Morand6, and the TRM-SLE Taskforce, 1Monash University, Melbourne, Victoria, Australia, 2Monash Health, Melbourne, Victoria, Australia, 3Monash Medical Centre, Richmond, Victoria, Australia, 4Monash Health, Clayton, Victoria, Australia, 5Monash University, Clayton, Victoria, Australia, 6School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: The success of randomised controlled trials (RCTs) in SLE has been hampered by limitations of current outcome measures, contributing to negative or discordant trial…
  • Abstract Number: 2426 • ACR Convergence 2024

    Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach

    Michaela Koehm1, Samuel Rischke2, Robert Gurke3, Gerd Geißlinger4 and Frank Behrens1, 1University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 2Goethe University Frankfurt, Institute of Clinical Pharmacology, Frankfurt, Germany, 3Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, 4Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a very heterogeneous clinical presentation and severity. Despite the variety of treatment options available,…
  • Abstract Number: 2547 • ACR Convergence 2024

    Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

    Cecilia Stumpf1, Vanessa Rodriguez1 and Carla Cuda2, 1Northwestern University, Chicago, 2Northwestern University, Chicago, IL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
  • Abstract Number: 2622 • ACR Convergence 2024

    Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring

    Emily Smitherman1, Justin Leach1, Aimee Hersh2, Melissa Mannion1, Jinoos Yazdany3 and Jeffrey Curtis4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Utah, Salt Lake City, UT, 3UCSF, San Francisco, CA, 4University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Poorly controlled childhood-onset lupus nephritis (cLN) can lead to end-stage kidney disease (ESKD), requiring kidney replacement therapies with substantial financial and quality of life…
  • Abstract Number: 0094 • ACR Convergence 2024

    Small GTPase Rab4A Regulates Mouse Behavior Through Altered Serum Serotonin Levels and Microglial mTORC1 Activation in Lupus-prone B6.TC Mice

    Thomas Winans1, Xiaojing Wang2, Joshua Lewis2, Jessica Nolan1, Laurence Morel3 and Andras Perl4, 1SUNY Upstate Medical University, Syracuse, 2SUNY Upstate Medical University, Syracuse, NY, 3University of Texas health San Antonio, San Antonio, TX, 4SUNY, Syracuse, NY

    Background/Purpose: Rab4A is a small GTPase that is overexpressed in patients and mice with systemic lupus erythematosus (SLE, PubMed ID: 23897774; PubMed ID 31805010). Rab4A…
  • Abstract Number: 0169 • ACR Convergence 2024

    Impact of Sense of Control Among People Living with SLE

    Amanda Eudy1, S. Sam Lim2, Charmayne M. Dunlop-Thomas3, Jinoos Yazdany4, Patti Katz5 and Laura Plantinga6, 1Duke University, Raleigh, NC, 2Emory University, Atlanta, GA, 3Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, 4University of California San Francisco, San Francisco, CA, 5UCSF, San Rafael, CA, 6University of California, San Francisco, San Francisco, CA

    Background/Purpose: SLE is a disease characterized by cycles of remitting and relapsing symptoms that can be unpredictable, stressful, and cause an individual to feel they…
  • Abstract Number: 0194 • ACR Convergence 2024

    Machine Learning Methods to Predict Cardiovascular Risk in Hispanic Patients with Systemic Lupus Erythematosus

    Ariana Gonzalez-Melendez1, Jeann Hernandez-Franco2, Dylan Cedres-Rivera3 and Abiel Roche-Lima3, 1University of Puerto Rico - Medical Science Campus, Guaynabo, PR, 2University of Puerto Rico, San Juan, PR, Puerto Rico, 3Center for Collaborative Research in Health Disparities, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, San Juan, PR, Puerto Rico

    Background/Purpose: The most common cause of death among patients with systemic lupus erythematosus (SLE) is cardiovascular disease (CVD). Previous studies have performed cardiovascular risk stratification;…
  • Abstract Number: 0362 • ACR Convergence 2024

    Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus

    Anna Deck1, Paula Caras2, Kiran Singh3, Monique Gore-Massy4, Faye Chiu5, Sara Folta6 and Shanthini Kasturi3, 1Tufts University School of Medicine, Portland, ME, 2Tufts University School of Medicine, Boston, MA, 3Tufts Medical Center, Boston, MA, 4Lupus Foundation of America, New Jersey, 5N/A, New York City, NY, 6Tufts University/Tufts University Friedman School of Nutrition, Boston, MA

    Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
  • Abstract Number: 0448 • ACR Convergence 2024

    A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities

    Divya Singh1, Maya Faison2, Molly Leavitt3, Megan Clowse4 and Cuoghi Edens5, 1University of Chicago, Chicago, IL, 2University of Chicago, Chapel Hill, NC, 3MacNeal Hospital/Loyola Medicine, Chicago, IL, 4Duke University, Chapel Hill, NC, 5Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL

    Background/Purpose: Nearly half of systemic lupus erythematosus (SLE) patients will experience pregnancy complications. These complications include increased rates of prematurity, miscarriage, pre-eclampsia, and mortality. Maternal…
  • Abstract Number: 0620 • ACR Convergence 2024

    Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial

    Benjamin A. Fisher1, Hendrika Bootsma2, Vibeke Strand3, Wan-Fai Ng4, Thomas Wegman5, Brandon Becker6, Jiyoon Choi6, Antoine Sreih6, Leo Chen7, Antonia Christodoulou6 and Eric Morand8, 1University of Birmingham, Birmingham, United Kingdom, 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 3Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 4Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, 5Bristol Myers Squibb, Beaver Falls, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Richmond, BC, Canada, 8School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
  • Abstract Number: 0641 • ACR Convergence 2024

    Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients

    Katherine Chakrabarti1, Apurba Chakrabarti2, Emily Lewis2 and William McCune3, 1University of Michigan, Ann Arbor, MI, 2University of Michigan Hospital, Ann Arbor, MI, 3U Michigan, Ann Arbor, MI

    Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
  • Abstract Number: 0657 • ACR Convergence 2024

    Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis

    Jagan K L1, Augustine Jose2, Vishnupriya G1, Dellan S1, Dhanush S1, Samskruthi Reddy Tokala1, Bhavana Mashetty1, Chengappa Kavadichanda3, Sachith ganapathy1, Aishwarya Gopal4, Rithik Roshan1, Sareddy Sai vignesh Reddy1, Sonal Mehra5, Molly Thabah1 and Vir Singh Negi6, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, 2Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, 4Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 5JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, 6AIIMS, Bilaspur, Puducherry, Puducherry, India

    Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
  • Abstract Number: 0676 • ACR Convergence 2024

    Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research

    Jeanette Andersen1, Ina Meyer2, Neeta Camadoo3, Tracy Machado4, Shreya Saraf4 and Mohamed Akrout2, 1Lupus Europe, Brussels, Belgium, 2F. Hoffmann-La Roche Ltd, Basel, 3Roche Products Ltd, Welwyn Garden City, 4Elma Research International, London

    Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that affects multiple organs, including the skin, joints, lungs, heart, kidneys and brain.…
  • Abstract Number: L02 • ACR Convergence 2023

    Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE

    John Huizar1, Victoria Rael2, Julian Yano2, Leianna Slayden3, Madeleine Weiss4, Robert Saxton4, Bo Liu5, Olivia Majer6 and Gregory Barton7, 1UCSF, San Francisco, CA, 2Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, UC Berkeley, Berkeley, CA, 3HHMI at UC Berkeley, Berkeley, CA, 4UC Berkeley, Berkeley, CA, 5Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shangai, China, 6Max Planck Institute for Infection Biology, Berlin, Germany, 7UC Berkeley / HHMI, Berkeley, CA

    Background/Purpose: Endosomal nucleic acid-sensing toll-like receptors 3, 7 and 9 are key innate immune sensors of dsRNA, ssRNA and ssDNA, respectively, whose activities must be…
  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology